Immunotherapy has no added impact on QoL for early breast cancer patients on chemotherapy

A recent analysis of the IMpassion031 study and patient-reported outcomes has showed that introducing immunotherapy into a regimen of chemotherapy in early breast cancer patients does not affect quality of life (QoL). The study, due to be presented at the 2020 San Antonio Breast Cancer Symposium (8–11 December), builds on earlier work that demonstrates immune checkpoint inhibitors can improve response rates to chemotherapy in triple-negative breast cancer (TNBC). TNBC tend to grow faster than other forms of breast cancer and often carry a worse prognosis. Trials investigating immunotherapeutics for the disease seek to increase the treatment options available to patients...